Setting research priorities to reduce global mortality from preterm birth and low birth weight by 2015. by Bahl, Rajiv et al.
Griffiths, UK; Edmond, K; Hajjeh, R (2009) Is hib vaccine of eco-
nomic value in South Korea? Journal of Korean medical science, 24
(1). p. 187. ISSN 1011-8934
Downloaded from: http://researchonline.lshtm.ac.uk/5727/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
We welcome the article from Shin and colleagues on the
cost-benefit of Haemophilus influenzae type b (Hib) immu-
nization in Korea (1). The introduction of Hib vaccine into
national immunization programmes has increased consider-
ably during the past few years. While 91 countries had intro-
duced the vaccine in 2005, 138 had done so in 2008 (2). Thir-
ty-three of these additional 46 countries receive support from
the GAVI Alliance (formerly the Global Alliance for Vaccines
and Immunization) for Hib vaccine, while 13 countries have
introduced the vaccine with government funds (3). In Asia,
the large countries of India, Pakistan and Bangladesh are cur-
rently introducing the vaccine.
The overall conclusion made by Shin et al. (1) is that Hib
vaccine is not economically efficient enough to introduce in
Korea, partly due to the relatively high price of Hib vaccine
and also due to the low Hib disease incidence. We wish to
question this conclusion and some of the assumptions made
to derive it. Firstly, Shin et al. used a public sector Hib vac-
cine price of US$20 per dose which seems unrealistically high.
There are no published records of governments paying such
a high public sector price for Hib vaccine. The US public
sector price is between US$9 and US$11 per dose (4). In Aus-
tralia, the government pays US$8 per dose (5). Shin et al. (1)
states that if the price was less than US$16 per dose the vac-
cine would be economically efficient. Hence, if the analysis
in the paper had been based on a public sector price compa-
rable to other countries, the overall conclusion would have
been opposite to their conclusion. The vaccine is in fact cost-
saving. Secondly, the assumption made about Hib pneumo-
nia incidence is unclear. The authors cite a reference from
the United States for the ratio of pneumonia to meningitis
incidence (6), which included only the incidence for inva-
sive Hib disease and not all Hib pneumonias, and indicated
that the number of meningitis cases is far higher than the
number of pneumonia cases. However, the calculations used
to estimate the pneumonia burden of disease were not stat-
ed clearly, and there are problems in extrapolating data from
countries with such different demographics. In fact, Hib
pneumonia is commonly thought to be much more preva-
lent than Hib meningitis in Asia (7). Lastly, we disagree
with the underlying notion of Shin et al. that economic effi-
ciency is only achieved if an intervention is proven to be cost-
saving. Governments and policy makers are normally pre-
pared to pay for improvement in the health of their popula-
tions. Economic analysis should, therefore, be used as one of
many factors to guide the decision to choose among alterna-
tive health technologies.
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